For adults with Chronic Idiopathic Constipation (CIC)

Help identify patients with CIC that may be seeking a different treatment approach

The checklist below may help determine whether your patients may be looking for something that works differently. 

SELECT IMPORTANT SAFETY INFORMATION

 Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Patient ID Tool

With your CIC patient in mind, going through this checklist may help you uncover if they are looking for a different treatment approach.

Want to save a copy of this checklist to use later? Click here to download the PDF.

Have your patients...

Dosing icon

Expressed frustration with recurring symptoms?

Wrist watch

Had less than 3 complete
spontaneous bowel
movements per week?

Fork, spoon and knife

Felt a sense of
incomplete evacuation?

Asked about
dosing frequency?

Stopped taking their
CIC medication as prescribed?

Colonic dysmotility could be a factor affecting your CIC patients.1

Consider a prokinetic approach for patients looking for a treatment that works differently.

Interested in learning about the
Mechanism of Action for Motegrity?

Not a real patient

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

INDICATION

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

Reference:

Reference: 1. Dinning PG, Di Lorenzo C. Best Pract Res Clin Gastroenterol. 2011;25(1):89-101.